secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001104659-25-044126
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.
- Outstanding shares will reduce from about 23.3M to approximately 833,620.
- No fractional shares issued; fractional shares rounded up to nearest whole share.
- Effective date to be announced at least two business days prior to implementation.
- Split designed to meet Nasdaq minimum bid price requirement for continued listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925044126/0001104659-25-044126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925044126/tm2513881d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer